HuMax-CD20 in Chronic Lymphocytic Leukemia

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Chronic Lymphocytic Leukemia

In brief

The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia.

Key facts

Study ID

NCT00093314

Run by

GlaxoSmithKline

People needed

0

Starts

2004-10-01

Expected to finish

2007-01-01

Last updated by the study team

2015-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chronic Lymphocytic Leukemia
• Circulating lymphocytes above a specific level
• Circulating lymphocytes showing certain markers

You may not qualify if…

• Previous treatment with rituximab or alemtuzumab within 6 months prior to enrollment in study.
• Previous stem cell transplantation.
• Received any of the following treatments within 4 weeks prior to entering this trial: A) Anti-cancer therapy, B) Glucocorticoids unless less than 10 mg per day, C) Radiotherapy.
• HIV positivity.
• Hepatitis B or hepatitis C.
• Other cancerous diseases, except certain skin cancers and cervix cancer.
• Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, heart, hormonal, nerve or blood diseases.
• Participation in another trial with a different new drug 4 weeks prior to enrollment in study.
• Current participation in any other clinical study.
• Pregnant or breast-feeding women.
• Women of childbearing age who are unable or unwilling to use adequate contraception.

Where it is running

• University of Iowa, Hospitals and Clinics — Iowa City, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.